Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy
- PMID: 15662130
- DOI: 10.4161/cbt.3.12.1369
Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy
Abstract
Antiangiogenic or metronomic chemotherapy, the frequent administration of conventional cytotoxic agents at low doses, is believed to target activated tumor endothelial cells. The mechanisms of action of such regimen remain poorly understood. In the March 2004 issue of Cancer Research, Hamano et al. demonstrated that low-dose cyclophosphamide inhibits tumor growth by upregulating the endogenous angiogenesis inhibitor thrombospondin-1 in tumor and perivascular cells. Thrombospondin-1, in turn, promotes endothelial cell apoptosis. It was also proposed that thrombospondin-1 levels might be used as a surrogate marker to monitor response to low-dose cyclophosphamide therapy in the clinic.
Similar articles
-
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.J Clin Oncol. 2005 Feb 10;23(5):939-52. doi: 10.1200/JCO.2005.07.093. Epub 2004 Nov 22. J Clin Oncol. 2005. PMID: 15557593
-
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.Mol Cancer Ther. 2008 Jan;7(1):79-89. doi: 10.1158/1535-7163.MCT-07-0584. Mol Cancer Ther. 2008. PMID: 18202011 Free PMC article.
-
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.Int J Cancer. 2009 Jun 15;124(12):2989-96. doi: 10.1002/ijc.24305. Int J Cancer. 2009. PMID: 19319982
-
Metronomic chemotherapy: Back to the future!Drug News Perspect. 2010 Mar;23(2):143-51. doi: 10.1358/dnp.2010.23.2.1475913. Drug News Perspect. 2010. PMID: 20369080 Review.
-
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.Prog Exp Tumor Res. 2003;37:179-92. doi: 10.1159/000071373. Prog Exp Tumor Res. 2003. PMID: 12795055 Review.
Cited by
-
Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?J Cell Mol Med. 2008 Dec;12(6B):2704-16. doi: 10.1111/j.1582-4934.2008.00255.x. Epub 2008 Feb 4. J Cell Mol Med. 2008. PMID: 18266977 Free PMC article.
-
Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.Clin Cancer Res. 2012 Aug 1;18(15):4114-21. doi: 10.1158/1078-0432.CCR-11-3250. Epub 2012 Jun 12. Clin Cancer Res. 2012. PMID: 22693353 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources